Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders.
Emalex Biosciences has raised $270.0M in total funding. The most recent round was Series D. The last funding was announced in November 2022.
Emalex Biosciences's investors include Valor Equity Partners, Bain Capital Life Sciences, Fidelity, Horizon Technology Finance, Paragon Biosciences.
Emalex Biosciences is headquartered in Chicago, United States.
Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders.
Emalex Biosciences is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Emalex Biosciences — Funding & Investors." VCBacked, November 3, 2022, https://www.vcbacked.co/company/emalex-biosciences. Accessed September 30, 2026.
VCBacked. (2022). Emalex Biosciences — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/emalex-biosciences
{{cite web |title=Emalex Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/emalex-biosciences |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated